Haleon PLC Directorate Change

RNS Number : 8322M

Haleon PLC

01 May 2024

 

 

 

 

Haleon plc announces changes to the Board

 

 

1 May 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that following Deirdre Mahlan's appointment as President, Chief Executive Officer and Chairperson of the Board of The Duckhorn Portfolio, Inc. (NYSE: NAPA), Deirdre will be stepping down from her role as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon. Deirdre has agreed to continue as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon until a successor has been identified.

 

 

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Deirdre for her considerable contributions to the Board and for chairing the Audit & Risk Committee. I wish her all the best for the future. A search for her successor is now underway."

 

 

 

 

Contacts

Zoë Bird                [phone]

Sonya Ghobrial      [phone]

Email: [e-mail]

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BOAUPUMUAUPCGUG